Overview

SCIENTIFIC SCORE
Possibly Effective
Based on 27 Researches
7.6
USERS' SCORE
Good
Based on 2 Reviews
8.3
Supplement Facts
Serving Size: 2 Veg Capsules
Amount Per Serving
%DV
Vitamin D (as Ergocalciferol)
10 mcg (400 IU)
50%
Calcium (from Fossilized Coral Calcium)
500 mg
38%
Magnesium (from Magnesium Oxide, Citrate and Aspartate)
250 mg
60%
Fossilized Coral Calcium
1.43 g (1,430 mg)

Top Medical Research Studies

We investigated the clinical safety and performance of a new magnesium scaffold known as DREAMS 3G. This innovative treatment aims to match the effectiveness of drug-eluting stents in coronary interventions.

Over one year, a total of 116 patients were monitored, showing promising results with minimal lumen loss and no adverse events like cardiac death or major thrombosis. Despite a few revascularization interventions, the scaffold appears to be a viable alternative.

Overall, our findings support its potential use in heart treatments.
Read More
9
Vitamin D counteracts blood clotting
Our research focused on understanding how Vitamin D (VitD) might influence blood clotting, especially in the context of COVID-19. We found that when human endothelial cells were exposed to IL-6—an inflammatory cytokine associated with severe COVID-19—it led to dysfunction in these cells. This dysfunction was marked by increased levels of Tissue Factor (TF) and cell adhesion molecules (CAMs), which promote blood clotting.

Remarkably, when we treated these endothelial cells with VitD, we observed a reversal of these harmful effects. VitD appeared to inhibit the expression of TF and CAMs and even modulated the levels of the ACE2 receptor, which is crucial for the entry of the virus into cells. Our findings suggest that VitD could play a protective role against the blood clotting complications associated with COVID-19 by counteracting IL-6's effects on endothelial cells.

Overall, this study paves the way for further research into VitD as a potential therapeutic option for mitigating thrombotic risks in COVID-19 patients.
Read More
9
Magnesium nanoparticles enhance clotting time
We investigated the effects of magnesium oxide nanoparticles, created using fruit extract, on blood clotting and oxidative stress. Our experiments showed that these nanoparticles significantly extended clotting time, indicating an anticoagulant effect. They also effectively reduced damage to red blood cells and various tissues in laboratory tests, helping to restore their function. Importantly, we found these nanoparticles non-toxic, suggesting they could be a promising treatment option for oxidative stress-related conditions without adverse side effects. However, further research is needed to fully understand their potential in clinical applications.
Read More

Most Useful Reviews

9
Calcium level normalised
3 people found this helpful
Following the intake of large doses of vitamin D3, my tests indicated an excess of ionised calcium in my blood. To rectify this, my doctor recommended coral calcium, which has effectively accomplished its purpose.
Read More
6
Joint pulsation relief
4 people found this helpful
I've been consuming this calcium supplement for around a month. There was a deficiency of calcium in my blood, resulting in a pulsation sensation in my joints. I haven't yet undergone further testing, but the ripple effect has ceased. I will update my feedback once I've completed my calcium analysis. I started with two capsules and then reduced it to one.
Read More

Medical Researches

SCIENTIFIC SCORE
Possibly Effective
Based on 27 Researches
7.6
  • All Researches
9
Vitamin D counteracts blood clotting
Our research focused on understanding how Vitamin D (VitD) might influence blood clotting, especially in the context of COVID-19. We found that when human endothelial cells were exposed to IL-6—an inflammatory cytokine associated with severe COVID-19—it led to dysfunction in these cells. This dysfunction was marked by increased levels of Tissue Factor (TF) and cell adhesion molecules (CAMs), which promote blood clotting.

Remarkably, when we treated these endothelial cells with VitD, we observed a reversal of these harmful effects. VitD appeared to inhibit the expression of TF and CAMs and even modulated the levels of the ACE2 receptor, which is crucial for the entry of the virus into cells. Our findings suggest that VitD could play a protective role against the blood clotting complications associated with COVID-19 by counteracting IL-6's effects on endothelial cells.

Overall, this study paves the way for further research into VitD as a potential therapeutic option for mitigating thrombotic risks in COVID-19 patients.
Read More
We explored the role of calcium in promoting blood coagulation using a new zeolite-embedded regenerated cellulose aerogel (Z-RCA). This innovative hemostatic agent was designed to minimize common issues seen with previous zeolite-based products, like heat-induced tissue damage and unwanted blood clotting elsewhere in the body.

Our results showed that this aerogel effectively absorbed blood while releasing calcium ions, which play a crucial role in the blood clotting process. By combining the properties of zeolite and the calcium-releasing ability of the aerogel, we found that Z-RCA not only facilitated quicker blood clotting but did so safely, with less risk of adverse effects.

In animal trials, we observed that Z-RCA stopped bleeding faster than existing options like Quikclot and notably reduced blood loss by over 62%. This combination of effectiveness and safety makes Z-RCA a promising solution for achieving efficient hemostasis during emergencies.
Read More
9
Magnesium nanoparticles enhance clotting time
We investigated the effects of magnesium oxide nanoparticles, created using fruit extract, on blood clotting and oxidative stress. Our experiments showed that these nanoparticles significantly extended clotting time, indicating an anticoagulant effect. They also effectively reduced damage to red blood cells and various tissues in laboratory tests, helping to restore their function. Importantly, we found these nanoparticles non-toxic, suggesting they could be a promising treatment option for oxidative stress-related conditions without adverse side effects. However, further research is needed to fully understand their potential in clinical applications.
Read More
8
Vitamin D linked to clot risk
We set out to understand how levels of vitamin D, specifically serum 25-hydroxyvitamin D (25OHD), influence the risk of developing venous thromboembolism (VTE), which includes serious conditions like deep vein thrombosis and pulmonary embolism. To do this, we examined a large cohort of nearly 378,000 participants, all free from VTE at the start of the study.

Our analysis focused on the relationship between vitamin D levels and VTE risk, particularly in individuals with diabetes compared to those without. Over a median follow-up period of 12.5 years, we recorded just over 10,600 new cases of VTE.

The findings were quite revealing: higher serum 25OHD concentrations were associated with a lower risk of VTE. This inverse relationship was especially pronounced in participants with diabetes. Interestingly, while we assessed various genetic factors that could influence VTE risk, they did not significantly change how vitamin D affected the likelihood of developing a blood clot.

However, we did find that specific genetic variations in the vitamin D receptor appeared to enhance the protective effects of vitamin D against VTE. Overall, we are encouraged by our findings, which suggest that maintaining sufficient levels of vitamin D may help reduce the risk of blood clots, particularly in those already managing diabetes.
Read More
8
Vitamin D mitigates platelet aggregation
We explored how 1,25-Dihydroxyvitamin D3, a form of vitamin D, can influence platelet aggregation, particularly in the context of COVID-19. Platelet hyperreactivity is a condition where platelets are overly reactive, contributing to blood clotting issues often seen in COVID-19 patients. Our investigation focused on how vitamin D might help mitigate these issues by examining its direct effects in the laboratory.

We found that vitamin D significantly reduced platelet aggregation, especially when this aggregation was heightened by the SARS-CoV-2 spike protein. This effect appears to be linked to vitamin D's ability to inhibit certain signaling pathways involved in platelet activation. Notably, the treatment reduced the activation of integrin αIIbβ3, which plays a key role in platelet spreading and clumping.

By utilizing a particular Src family kinase inhibitor, we confirmed that there are overlapping pathways being influenced, as both vitamin D and the inhibitor showed similar effects in lowering platelet responses. Our findings suggest that vitamin D could serve as a beneficial treatment to help manage clotting in COVID-19, though further exploration is necessary.
Read More

User Reviews

USERS' SCORE
Good
Based on 2 Reviews
8.3
  • All Reviews
  • Positive Reviews
  • Negative Reviews
9
Calcium level normalised
3 people found this helpful
Following the intake of large doses of vitamin D3, my tests indicated an excess of ionised calcium in my blood. To rectify this, my doctor recommended coral calcium, which has effectively accomplished its purpose.
Read More
6
Joint pulsation relief
4 people found this helpful
I've been consuming this calcium supplement for around a month. There was a deficiency of calcium in my blood, resulting in a pulsation sensation in my joints. I haven't yet undergone further testing, but the ripple effect has ceased. I will update my feedback once I've completed my calcium analysis. I started with two capsules and then reduced it to one.
Read More

Frequently Asked Questions

No FAQs are available for this product and symptom.

References

  1. Xiang H, Zhou C, Gan X, Huang Y, He P, et al. Relationship of Serum 25-Hydroxyvitamin D Concentrations, Diabetes, Vitamin D Receptor Gene Polymorphisms and Incident Venous Thromboembolism. Diabetes Metab Res Rev. 2025;41:e70014. doi:10.1002/dmrr.70014
  2. Rachman A, Iriani A, Irawan A, Juanputra S, Betsy R. Adequate serum 25-hydroxy-vitamin D levels are correlated with low anti-PF4 levels in mild COVID-19 Patients: An observational study. Medicine (Baltimore). 2024;103:e39252. doi:10.1097/MD.0000000000039252
  3. Wang R, Tian Z, Wang C, Zhang B, Zhu M, et al. 1,25-Dihydroxyvitamin D3 attenuates platelet aggregation potentiated by SARS-CoV-2 spike protein via inhibiting integrin αIIbβ3 outside-in signaling. Cell Biochem Funct. 2024;42:e4039. doi:10.1002/cbf.4039
  4. Andersen MK, Rüdiger IH, Vestergaard AL, Palarasah Y, Bor P, et al. Vitamin D Deficiency is Associated With Increased Plasminogen Activator Inhibitor 1/Plasminogen Activator Inhibitor 2 Ratio in Pregnancy. Clin Appl Thromb Hemost. 2023;29:10760296231201855. doi:10.1177/10760296231201855
  5. Şaylık F, Selçuk M, Akbulut T, Çınar T. The Association between Vitamin D Levels and Thrombus Burden in Patients with ST-Elevation Myocardial Infarction. J Tehran Heart Cent. 2022;17:48. doi:10.18502/jthc.v17i2.9835
  6. Uguz B, Oztas S, Zengin I, Topal D, Tiryakioglu SK, et al. Relationship between vitamin D deficiency and thrombus load in patients with ST-elevation myocardial infarction. Eur Rev Med Pharmacol Sci. 2022;26:7015. doi:10.26355/eurrev_202210_29885
  7. Hajimoradi B, Hosseini B, Alirezaei T, Pourmotahari F. 25-Hydroxy vitamin D level is associated with mean platelet volume in patients with acute coronary syndrome. Cardiovasc Hematol Disord Drug Targets. 2022. doi:10.2174/1871529X22666220418111905
  8. Hoek M, Schultz M, Alummoottil S, Aneck-Hahn N, Mathabe K, et al. Ex vivo Vitamin D supplementation improves viscoelastic profiles in prostate cancer patients. Clin Hemorheol Microcirc. 2022;81:221. doi:10.3233/CH-211353
  9. Cimmino G, Conte S, Morello M, Pellegrino G, Marra L, et al. Vitamin D Inhibits IL-6 Pro-Atherothrombotic Effects in Human Endothelial Cells: A Potential Mechanism for Protection against COVID-19 Infection?. J Cardiovasc Dev Dis. 2022;9. doi:10.3390/jcdd9010027
  10. Jin Z, Chen L, Liu X, Xia R, Li W, et al. Zeolite firmly anchored regenerated cellulose aerogel for efficient and biosafe hemostasis. Int J Biol Macromol. 2025;304:140743. doi:10.1016/j.ijbiomac.2025.140743
  11. Tran VA, Griffin EM, Elliott JD, Scholl RL, Hill RB, et al. Thrombotic Complications Associated With Right Atrial Lines in Neonates and Infants Undergoing Cardiac Surgery. Is Calcium Chloride a Culprit?. J Cardiothorac Vasc Anesth. 2025. doi:10.1053/j.jvca.2025.01.008
  12. Kim J, Kim M, Lee CS, Choi EY. Sufficient Magnesium Intake Reduces Retinal Vein Occlusion Risk: National Health and Nutrition Examination Survey Analysis. Nutrients. 2025;17. doi:10.3390/nu17071285
  13. Guo X, Zeng X, He Y, Zhang X, Shi W, et al. An Antibacterial, Antioxidant Adherent Sponge Constructed for Control of Arterial Bleeding Via Gallic Acid-Mediated Robust Assembly of Fibrous Clay in Collagen. ACS Appl Mater Interfaces. 2025;17:16489. doi:10.1021/acsami.4c19209
  14. Müller M, Ludwig L, Englert H, Riedl KA, Müller MC, et al. A novel stent flow chamber system demonstrates reduced thrombogenicity of bioresorbable magnesium scaffolds. Sci Rep. 2024;14:26691. doi:10.1038/s41598-024-77266-0
  15. Zhang J, Chen Z, Rao L, He Y. Coronary bioresorbable metallic stents: Advancements and future perspectives. J Cardiol. 2025;85:69. doi:10.1016/j.jjcc.2024.08.003
  16. Włodarczak A, Rola P, Włodarczak S, Szudrowicz M, Giniewicz K, et al. Two-Year Outcomes for Patients with Non-ST-Elevation Acute Coronary Syndrome Treated with Magmaris and Absorb Bioresorbable Scaffolds in Large-Vessel Lesions. J Pers Med. 2024;14. doi:10.3390/jpm14050540
  17. Galli S, Troiano S, Palloshi A, Rapetto C, Pisano F, et al. Comparison of acute versus stable coronary syndrome in patients treated with the Magmaris scaffold: Two-year results from the Magmaris Multicenter Italian Registry. Cardiovasc Revasc Med. 2023;57:53. doi:10.1016/j.carrev.2023.06.022
  18. Włodarczak A, Rola P, Barycki M, Furtan Ł, Łanocha M, et al. Mid-term safety and efficacy of magnesium bioresorbable vascular scaffolds - magmaris in diabetic population. 2-Years outcome in acute coronary syndrome cohort. Diab Vasc Dis Res. 2023;20:14791641231188705. doi:10.1177/14791641231188705
  19. Gotru SK, Mammadova-Bach E, Sogkas G, Schuhmann MK, Schmitt K, et al. MAGT1 Deficiency Dysregulates Platelet Cation Homeostasis and Accelerates Arterial Thrombosis and Ischemic Stroke in Mice. Arterioscler Thromb Vasc Biol. 2023;43:1494. doi:10.1161/ATVBAHA.122.318115
  20. Haude M, Wlodarczak A, van der Schaaf RJ, Torzewski J, Ferdinande B, et al. A new resorbable magnesium scaffold for de novo coronary lesions (DREAMS 3): one-year results of the BIOMAG-I first-in-human study. EuroIntervention. 2023;19:e414. doi:10.4244/EIJ-D-23-00326
  21. Wlodarczak A, Montorsi P, Torzewski J, Bennett J, Starmer G, et al. One- and two-year clinical outcomes of treatment with resorbable magnesium scaffolds for coronary artery disease: the prospective, international, multicentre BIOSOLVE-IV registry. EuroIntervention. 2023;19:232. doi:10.4244/EIJ-D-22-01069
  22. Haude M, Wlodarczak A, van der Schaaf RJ, Torzewski J, Ferdinande B, et al. Safety and performance of the third-generation drug-eluting resorbable coronary magnesium scaffold system in the treatment of subjects with de novo coronary artery lesions: 6-month results of the prospective, multicenter BIOMAG-I first-in-human study. EClinicalMedicine. 2023;59:101940. doi:10.1016/j.eclinm.2023.101940
  23. Pompei G, Campo G, Ruggiero R, Maffeo D, Sgura F, et al. Long-term outcomes of patients treated with sirolimus-eluting resorbable magnesium scaffolds: Insights from the SHERPA-MAGIC study. Int J Cardiol. 2023;383:1. doi:10.1016/j.ijcard.2023.04.029
  24. Fedele G, Castiglioni S, Maier JAM, Locatelli L. The Effects of Sirolimus and Magnesium on Primary Human Coronary Endothelial Cells: An In Vitro Study. Int J Mol Sci. 2023;24. doi:10.3390/ijms24032930
  25. Tonai K, Katayama S, Koyama K, Sata N, Tomioka Y, et al. Association between hypomagnesemia and coagulopathy in sepsis: a retrospective observational study. BMC Anesthesiol. 2022;22:359. doi:10.1186/s12871-022-01903-2
  26. Seguchi M, Aytekin A, Lenz T, Nicol P, Alvarez-Covarrubias HA, et al. Challenges of the newer generation of resorbable magnesium scaffolds: Lessons from failure mechanisms of the past generation. J Cardiol. 2023;81:179. doi:10.1016/j.jjcc.2022.09.003
  27. Venkatappa MM, Udagani C, Hanumegowda SM, Pramod SN, Venkataramaiah S, et al. Effect of Biofunctional Green Synthesized MgO-Nanoparticles on Oxidative-Stress-Induced Tissue Damage and Thrombosis. Molecules. 2022;27. doi:10.3390/molecules27165162
image